Cargando…
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
According to global cancer data, lung cancer was the leading cause of cancer-related death in 2020. With the diversification of treatment strategies, the survival outcomes of patients with advanced lung cancer have improved significantly, but the 5-year overall survival rate remains <20%. Epiderm...
Autores principales: | Sun, Ruizhu, Hou, Zhansheng, Zhang, Yankui, Jiang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555020/ https://www.ncbi.nlm.nih.gov/pubmed/36245822 http://dx.doi.org/10.3892/ol.2022.13528 |
Ejemplares similares
-
Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
por: Jiang, Zhansheng, et al.
Publicado: (2018) -
Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report
por: Xu, Li, et al.
Publicado: (2017) -
Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021) -
The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015) -
Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas – Implications for the progression of EGFR-mutated lung adenocarcinomas
por: Matsumura, Mai, et al.
Publicado: (2019)